AGE-RELATED MACULAR DEGENERATION (ARMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (ARMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (ARMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (ARMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Daily shot may slow blindness in dry AMD – major trial underway
Disease control OngoingThis phase 3 trial tests whether a daily injection of elamipretide can slow the loss of light-sensing cells in people with dry age-related macular degeneration (AMD), a leading cause of vision loss. About 313 adults aged 55 and older with early geographic atrophy will receive eit…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
Can your dinner plate protect your eyesight? new study investigates
Knowledge-focused OngoingThis study looks at how genetics, diet, lifestyle, and medications together influence the risk of age-related macular degeneration (AMD), a leading cause of vision loss. Researchers are studying 1800 adults to see if factors like the Mediterranean diet, exercise, and chronic medi…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (ARMD)
Phase: NA • Sponsor: Association for Innovation and Biomedical Research on Light and Image • Aim: Knowledge-focused
Last updated May 26, 2026 11:08 UTC